$ACAD insider trading
Over the last 12 months, Acadia Pharmaceuticals insiders reported no purchases and 18 sales totaling $3.5M across SEC Form 4 filings. 89% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.5M 18 events
- Events · 12m
- 18 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 89% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 20,141 | $29.16 | $587K | -22.9% | plan · 3 tranches |
| Jul 30, 2026 | Thompson Elizabeth H.Z.EVP, Head of Research & Dev · O | ▼ Sale | 16,558 | $26.13 | $433K | -46.6% | plan · 2 tranches |
| Jun 26, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 11,421 | $26.08 | $298K | -46.6% | plan |
| May 26, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 5,401 | $21.18 | $114K | -18.1% | — |
| May 4, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 3,506 | $21.79 | $76K | -5% | plan |
| May 4, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 1,332 | $21.79 | $29K | -4.4% | plan |
| Apr 7, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 2,709 | $22.2 | $60K | -4.1% | plan |
| Apr 7, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 1,030 | $22.2 | $23K | -3.6% | plan |
| Mar 26, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 7,385 | $21.55 | $159K | -10.9% | plan · 3 tranches |
| Mar 26, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 1,942 | $21.57 | $42K | -6.7% | plan · 3 tranches |
| Mar 25, 2026 | Thompson Elizabeth H.Z.EVP, Head of Research & Dev · O | ▼ Sale | 3,435 | $21.47 | $74K | -51.2% | plan |
| Mar 25, 2026 | Owen Adams CatherineChief Executive Officer · O·D | ▼ Sale | 11,641 | $21.47 | $250K | -44% | plan |
| Mar 25, 2026 | Rhodes Jennifer JEVP, CHIEF LEGAL OFFICER, SEC · O | ▼ Sale | 3,844 | $21.47 | $83K | -25.4% | plan |
| Feb 9, 2026 | Rhodes Jennifer JEVP, CHIEF LEGAL OFFICER, SEC · O | ▼ Sale | 6,950 | $23.38 | $162K | -47.7% | plan |
| Nov 18, 2025 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 10,262 | $23.69 | $243K | -16.1% | plan |
| Nov 18, 2025 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 4,084 | $23.69 | $97K | -14% | plan |
| Nov 10, 2025 | Daly James MD | ▼ Sale | 30,000 | $22.37 | $671K | -88.1% | — |
| Sep 15, 2025 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 3,498 | $23.65 | $83K | -7.5% | plan |
| Sep 2, 2025 | GAROFALO ELIZABETH A.D | ▼ Sale | 1,600 | $25.98 | $42K | -5.9% | — |
| Aug 18, 2025 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 22,000 | $25.18 | $554K | -35.4% | plan |
Every $ACAD filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Acadia Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ACAD feed.